Study on the Effect of Treatment Regiman Combined with Ruxolitinib on MPN Patients with Myelofibrosis and the Influencing Factors of Mutated Gene Load (PubMed, Zhongguo Shi Yan Xue Ye Xue Za Zhi) - Sep 29, 2026 - "Ruxolitinib combined with thalidomide, prednisone, androgen, interferon alpha and other drugs can improve the clinical symptoms of MPN patients with MF, shrink the spleen, and also have a positive effect on reducing the JAK2 mutation load."
Journal • Retrospective data • Tumor mutational burden • Hematological Disorders • Myelofibrosis • Myeloproliferative Neoplasm • Oncology • JAK2 • TMB
|
|
Chun-Kang Chang; Dong Wu; Duo-Er Wu; Jun-Ying Wu; Lu-Xi Song; Qi He; Yao Zhang; You-Shan Zhao
|